2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Related Products

PDF 0.73 MB

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0483
    Tioxolone
    		Inhibitor 98.24%
    Tioxolone is an inhibitor of the metalloenzyme carbonic anhydrase I and has anti-acne activity.
    Tioxolone
  • HY-118467
    Benzolamide
    		Inhibitor 98.07%
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
    Benzolamide
  • HY-142849
    Carbonic anhydrase inhibitor 2
    		Inhibitor 98.40%
    Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits.
    Carbonic anhydrase inhibitor 2
  • HY-N0085
    Dimethylfraxetin
    		Inhibitor 99.97%
    Dimethylfraxetin is a Carbonic anhydrase inhibitor, with a Ki value of 0.0097 μM.
    Dimethylfraxetin
  • HY-B0562
    Methyclothiazide
    		99.76%
    Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715). Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro.
    Methyclothiazide
  • HY-138365
    EMAC10101d
    		Inhibitor 99.89%
    EMAC10101d is a potent and selective toward hCA II inhibitor, with a Ki of 8.1 nM.
    EMAC10101d
  • HY-16726
    Polmacoxib
    		Inhibitor 99.70%
    Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase. Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models.
    Polmacoxib
  • HY-108316
    Sultiame
    		Inhibitor 99.76%
    Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
    Sultiame
  • HY-148135
    hCAI/II-IN-6
    		Inhibitor ≥98.0%
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
    hCAI/II-IN-6
  • HY-149301
    hCAIX-IN-18
    		Inhibitor 98.52%
    hCAIX-IN-18 (compound 30) is an inhibitor of carbonic anhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research.
    hCAIX-IN-18
  • HY-B0782S
    Acetazolamide-d3
    		Inhibitor 99.95%
    Acetazolamide-d3 is deuterium labeled Acetazolamide, which is a potent carbonic anhydrase (CA) inhibitor.
    Acetazolamide-d<sub>3</sub>
  • HY-B0782R
    Acetazolamide (Standard)
    		Inhibitor 99.69%
    Acetazolamide (Standard) is the analytical standard of Acetazolamide. This product is intended for research and analytical applications. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
    Acetazolamide (Standard)
  • HY-151916
    Enpp/Carbonic anhydrase-IN-1
    		Inhibitor 99.57%
    Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis.
    Enpp/Carbonic anhydrase-IN-1
  • HY-B0109
    Dorzolamide
    		Inhibitor
    Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
    Dorzolamide
  • HY-B0124A
    Zonisamide sodium
    		Inhibitor
    Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
    Zonisamide sodium
  • HY-B0124S
    Zonisamide-d4
    		Inhibitor 99.38%
    Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
    Zonisamide-d<sub>4</sub>
  • HY-152140
    hCAII-IN-8
    		Inhibitor 99.41%
    hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II.
    hCAII-IN-8
  • HY-147986
    hCA I-IN-2
    		Inhibitor
    hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively.
    hCA I-IN-2
  • HY-B0122A
    Topiramate lithium
    		Inhibitor
    Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate lithium
  • HY-155522
    WES-1
    		Inhibitor
    WES-1 (Compound 8g) is an inhibitor of carbonic anhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines.
    WES-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Carbonic Anhydrase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.